193 related articles for article (PubMed ID: 25232677)
1. Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.
Loriot Y; Mordant P; Dugue D; Geneste O; Gombos A; Opolon P; Guegan J; Perfettini JL; Pierre A; Berthier LK; Kroemer G; Soria JC; Depil S; Deutsch E
Cell Death Dis; 2014 Sep; 5(9):e1423. PubMed ID: 25232677
[TBL] [Abstract][Full Text] [Related]
2. Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
Némati F; de Montrion C; Lang G; Kraus-Berthier L; Carita G; Sastre-Garau X; Berniard A; Vallerand D; Geneste O; de Plater L; Pierré A; Lockhart B; Desjardins L; Piperno-Neumann S; Depil S; Decaudin D
PLoS One; 2014; 9(1):e80836. PubMed ID: 24454684
[TBL] [Abstract][Full Text] [Related]
3. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.
Kim KW; Moretti L; Mitchell LR; Jung DK; Lu B
Clin Cancer Res; 2009 Oct; 15(19):6096-105. PubMed ID: 19773376
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.
Ritter V; Krautter F; Klein D; Jendrossek V; Rudner J
Cell Death Dis; 2021 Jul; 12(7):694. PubMed ID: 34257274
[TBL] [Abstract][Full Text] [Related]
5. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
6. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
7. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.
Li JY; Li YY; Jin W; Yang Q; Shao ZM; Tian XS
J Exp Clin Cancer Res; 2012 Dec; 31(1):102. PubMed ID: 23259599
[TBL] [Abstract][Full Text] [Related]
8. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
9. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun SY; Ramalingam SS; Khuri FR; Curran WJ; Deng X
Cancer Res; 2013 Sep; 73(17):5485-96. PubMed ID: 23824742
[TBL] [Abstract][Full Text] [Related]
10. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
[No Abstract] [Full Text] [Related]
12. AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer.
Moretti L; Li B; Kim KW; Chen H; Lu B
J Thorac Oncol; 2010 May; 5(5):680-7. PubMed ID: 20354451
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
Li X; Zhu W; Chen Z; Luo L; Huang J; Zhang F; Li M; Guo Y; Guo L
Anticancer Drugs; 2014 Nov; 25(10):1152-64. PubMed ID: 25054270
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
Zinn RL; Gardner EE; Dobromilskaya I; Murphy S; Marchionni L; Hann CL; Rudin CM
Mol Cancer; 2013 Mar; 12():16. PubMed ID: 23452820
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
Jin J; Xiong Y; Cen B
Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
[TBL] [Abstract][Full Text] [Related]
16. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
17. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
Lam LT; Lin X; Faivre EJ; Yang Z; Huang X; Wilcox DM; Bellin RJ; Jin S; Tahir SK; Mitten M; Magoc T; Bhathena A; Kati WM; Albert DH; Shen Y; Uziel T
Mol Cancer Ther; 2017 Aug; 16(8):1511-1520. PubMed ID: 28468776
[TBL] [Abstract][Full Text] [Related]
18. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
[TBL] [Abstract][Full Text] [Related]
19. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
Loriot Y; Mordant P; Brown BD; Bourhis J; Soria JC; Deutsch E
Anticancer Res; 2010 Oct; 30(10):3869-78. PubMed ID: 21036697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
